Funding adds to $20 million already awarded by the U.S. Government for Anthim and the Heteropolymer Antibody technology.
Elusys Therapeutics was awarded a contract for $12 million to advance its late-stage anthrax therapeutic, Anthim. This project has been funded in whole or in part by the NIAID and the Biomedical Advanced Research and Development Authority (BARDA), of the Deparment of Health and Human Services.
To date Elusys says that it has received more than $32 million from NIAID/BARDA and the DoD in support of Anthim and the company’s Heteropolymer Antibody™ technology.
“Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA,” says Elizabeth Posillico, Ph.D., president and CEO of Elusys. “We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government’s Strategic National Stockpile.”
